Literature DB >> 29600017

Lobar or sublobar resection for stage I lung cancer: that is (still) the question!

Alfonso Fiorelli1, Domenico Loizzi2, Mario Santini1.   

Abstract

Entities:  

Year:  2018        PMID： 29600017      PMCID： PMC5863191          DOI： 10.21037/jtd.2017.11.127

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  25 in total

1.  Stage I non-small-cell lung cancer: long-term results of lobectomy versus sublobar resection from the Polish National Lung Cancer Registry.

Authors:  Robert Dziedzic; Wojciech Zurek; Tomasz Marjanski; Piotr Rudzinski; Tadeusz M Orlowski; Wioletta Sawicka; Michal Marczyk; Joanna Polanska; Witold Rzyman
Journal:  Eur J Cardiothorac Surg       Date:  2017-08-01       Impact factor: 4.191

2.  A phase III randomized trial of lobectomy versus limited resection for small-sized peripheral non-small cell lung cancer (JCOG0802/WJOG4607L).

Authors:  Kenichi Nakamura; Hisashi Saji; Ryu Nakajima; Morihito Okada; Hisao Asamura; Taro Shibata; Shinichiro Nakamura; Hirohito Tada; Masahiro Tsuboi
Journal:  Jpn J Clin Oncol       Date:  2009-11-22       Impact factor: 3.019

3.  Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group.

Authors:  R J Ginsberg; L V Rubinstein
Journal:  Ann Thorac Surg       Date:  1995-09       Impact factor: 4.330

4.  Incidence, Risk Factors, and Analysis of Survival of Unexpected N2 Disease in Stage I Non-Small Cell Lung Cancer.

Authors:  Alfonso Fiorelli; Dariusz Sagan; Lukasz Mackiewicz; Lucio Cagini; Elisa Scarnecchia; Paolo Chiodini; Francesco Paolo Caronia; Francesco Puma; Mario Santini; Mark Ragusa
Journal:  Thorac Cardiovasc Surg       Date:  2015-01-28       Impact factor: 1.827

Review 5.  Lung segmentectomy: does it offer a real functional benefit over lobectomy?

Authors:  Anne Charloux; Elisabeth Quoix
Journal:  Eur Respir Rev       Date:  2017-10-25

6.  Sublobectomy versus lobectomy for stage I non-small-cell lung cancer, a meta-analysis of published studies.

Authors:  Jiang Fan; Lei Wang; Ge-Ning Jiang; Wen Gao
Journal:  Ann Surg Oncol       Date:  2011-07-19       Impact factor: 5.344

7.  Sublobar resection versus lobectomy for stage I non-small cell lung cancer: an appropriate choice in elderly patients?

Authors:  Alfonso Fiorelli; Francesco Paolo Caronia; Niccolò Daddi; Domenico Loizzi; Luca Ampollini; Nicoletta Ardò; Luigi Ventura; Paolo Carbognani; Rossella Potenza; Francesco Ardissone; Francesco Sollitto; Sandro Mattioli; Francesco Puma; Mario Santini; Mark Ragusa
Journal:  Surg Today       Date:  2016-04-16       Impact factor: 2.549

8.  Choice of Surgical Procedure for Patients With Non-Small-Cell Lung Cancer ≤ 1 cm or > 1 to 2 cm Among Lobectomy, Segmentectomy, and Wedge Resection: A Population-Based Study.

Authors:  Chenyang Dai; Jianfei Shen; Yijiu Ren; Shengyi Zhong; Hui Zheng; Jiaxi He; Dong Xie; Ke Fei; Wenhua Liang; Gening Jiang; Ping Yang; Rene Horsleben Petersen; Calvin S H Ng; Chia-Chuan Liu; Gaetano Rocco; Alessandro Brunelli; Yaxing Shen; Chang Chen; Jianxing He
Journal:  J Clin Oncol       Date:  2016-07-05       Impact factor: 44.544

9.  Survival following lobectomy vs limited resection for stage I lung cancer: a meta-analysis.

Authors:  H Nakamura; N Kawasaki; M Taguchi; K Kabasawa
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

10.  Sublobectomy versus lobectomy for stage IA (T1a) non-small-cell lung cancer: a meta-analysis study.

Authors:  Yaxin Liu; Cheng Huang; Hongsheng Liu; Yeye Chen; Shanqing Li
Journal:  World J Surg Oncol       Date:  2014-05-01       Impact factor: 2.754
View more
  3 in total

1.  Lobectomy versus segmentectomy and wedge resection in the treatment of stage I non-small cell lung cancer.

Authors:  Robert Dziedzic; Witold Rzyman
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

2.  Is video-assisted thoracoscopic lobectomy associated with higher overall costs compared with open surgery? Results of best evidence topic analysis.

Authors:  Alfonso Fiorelli; Stefano Forte; Francesco Paolo Caronia; Francesco Ferrigno; Mario Santini; René Horsleben Petersen; Wentao Fang
Journal:  Thorac Cancer       Date:  2021-02-05       Impact factor: 3.500

3.  Adjuvant chemotherapy, extent of resection, and immunoistochemical neuroendocrine markers as prognostic factors of early-stage large-cell neuroendocrine carcinoma.

Authors:  Claudio Andreetti; Mohsen Ibrahim; Antonio Gagliardi; Camilla Poggi; Giulio Maurizi; Domenico Armillotta; Valentina Peritone; Leonardo Teodonio; Erino Angelo Rendina; Federico Venuta; Marco Anile; Giovanni Natale; Mario Santini; Alfonso Fiorelli
Journal:  Thorac Cancer       Date:  2022-02-16       Impact factor: 3.500
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.